Abstract
An estimated 20% to 30% of all neuroendocrine tumours originate in the bronchial tree and lungs. According to the 2015 World Health Organization categorization, these tumours are separated into four subtypes characterized by increasing biological aggressiveness: typical carcinoid, atypical carcinoid, large-cell neuroendocrine carcinoma and small-cell carcinoma. Although typical and atypical lung carcinoids account for less than 1-5% of all pulmonary malignancies, the incidence of these neoplasms has risen significantly in recent decades. Surgery is the treatment of choice for loco-regional disease but for advanced lung carcinoids there is no recognized standard of care and successful management requires a multidisciplinary approach. The aim of this review is to provide a useful guide for the clinical management of lung carcinoids.
Original language | English |
---|---|
Pages (from-to) | 167-176 |
Number of pages | 10 |
Journal | Critical Reviews in Oncology/Hematology |
Volume | 100 |
DOIs | |
Publication status | Published - Apr 1 2016 |
Keywords
- Atypical carcinoids
- Lung carcinoids
- Neuroendocrine tumours
- Typical carcinoids
ASJC Scopus subject areas
- Oncology
- Hematology
- Geriatrics and Gerontology